| Autor: |
Sayyid RK; Division of Urology, Department of Surgical Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada., Bernardino R; Division of Urology, Department of Surgical Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada., Chavarriaga J; Division of Urology, Department of Surgical Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada., Gleave A; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada., Kumar R; Division of Urology, Department of Surgical Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada., Fleshner NE; Division of Urology, Department of Surgical Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada. |
| Abstrakt: |
Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-671/coif). Neil E. Fleshner reports grants and personal fees from Janssen, Astellas, Bayer, and Sanofi; grants from Nucleix, Progenix, and the Ontario Institute for Cancer Research; and personal fees from Amgen, Abbvie, Ferring, Verity Pharmaceuticals, and POINTBiopharma outside the submitted work. The other authors have no conflicts of interest to declare. |
